View Item 

Show simple item record

The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
dc.contributor.authorSukul, Devraj
dc.contributor.authorSeth, Milan
dc.contributor.authorSchreiber, Theodore
dc.contributor.authorHanzel, George
dc.contributor.authorKhandelwal, Akshay
dc.contributor.authorCannon, Louis A.
dc.contributor.authorLalonde, Thomas A.
dc.contributor.authorGurm, Hitinder S.
dc.date.accessioned2017-10-05T18:19:31Z
dc.date.available2018-11-01T16:42:00Zen
dc.date.issued2017-08
dc.identifier.citationSukul, Devraj; Seth, Milan; Schreiber, Theodore; Hanzel, George; Khandelwal, Akshay; Cannon, Louis A.; Lalonde, Thomas A.; Gurm, Hitinder S. (2017). "The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)." Journal of Interventional Cardiology 30(4): 291-300.
dc.identifier.issn0896-4327
dc.identifier.issn1540-8183
dc.identifier.urihttps://hdl.handle.net/2027.42/138368
dc.publisherWiley Periodicals, Inc.
dc.subject.othertransfusion
dc.subject.otherbleeding
dc.subject.otherglycoprotein inhibitors
dc.subject.otheroutcomes
dc.subject.otherPCI
dc.subject.otherdialysis
dc.titleThe comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138368/1/joic12388.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138368/2/joic12388_am.pdf
dc.identifier.doi10.1111/joic.12388
dc.identifier.sourceJournal of Interventional Cardiology
dc.identifier.citedreferenceHansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Stat. 2006; 15: 609 – 627.
dc.identifier.citedreferenceChew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE‐2 trial). Am J Cardiol. 2005; 95: 581 – 585.
dc.identifier.citedreferenceMehran R, Nikolsky E, Lansky AJ, et al. Impact of chronic kidney disease on early (30‐day) and late (1‐year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009; 2: 748 – 757.
dc.identifier.citedreferenceBest PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002; 39: 1113 – 1119.
dc.identifier.citedreferenceCasserly LF, Dember LM. Thrombosis in end‐stage renal disease. Semin Dial. 2003; 16: 245 – 256.
dc.identifier.citedreferenceCoca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006; 296: 1377 – 1384.
dc.identifier.citedreferenceTsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009; 302: 2458 – 2464.
dc.identifier.citedreferenceBarnes GD, Stanislawski MA, Liu W, et al. Use of contraindicated antiplatelet medications in the setting of percutaneous coronary intervention: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circ Cardiovasc Qual Outcomes. 2016; 9: 406 – 413.
dc.identifier.citedreferenceMelloni C, James SK, White JA, et al. Safety and efficacy of adjusted‐dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011; 162: 884.e1 – 892.e1.
dc.identifier.citedreferenceRandomised placebo‐controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT‐II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis‐II. Lancet. 1997; 349: 1422 – 1428.
dc.identifier.citedreferenceESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo‐controlled trial. Lancet. 2000; 356: 2037 – 2044.
dc.identifier.citedreferenceIntegrilin(R) (eptifibatide). Full prescribing information. Available at: https://www.merck.com/product/usa/pi_circulars/i/integrilin/integrilin_pi.pdf. Accessed: August 13, 2016.
dc.identifier.citedreferenceKline‐Rogers E, Share D, Bondie D, et al. Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002; 15: 387 – 392.
dc.identifier.citedreferenceMoscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation. 2006; 113: 814 – 822.
dc.identifier.citedreferenceNCDR CathPCI Registry v4.4 Coder’s Data Dictionary. Available at: https://www.ncdr.com/WebNCDR/docs/public-data-collection-documents/cathpci_v4_codersdictionary_4-4.pdf. Accessed: July 28, 2016.
dc.identifier.citedreferenceLevine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44 – e122.
dc.identifier.citedreferenceR Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
dc.identifier.citedreferenceDe Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST‐segment elevation myocardial infarction: a meta‐analysis of randomized trials. JAMA. 2005; 293: 1759 – 1765.
dc.identifier.citedreferenceKastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR‐REACT 2 randomized trial. JAMA. 2006; 295: 1531 – 1538.
dc.identifier.citedreferenceGurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008; 51: 529 – 535.
dc.identifier.citedreferenceSabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med. 2000; 109: 224 – 237.
dc.identifier.citedreferenceTopol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344: 1888 – 1894.
dc.identifier.citedreferenceShare DA, Campbell DA, Birkmeyer N, et al. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff. 2011; 30: 636 – 645.
dc.identifier.citedreferenceLong CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004; 38: 853 – 858.
dc.identifier.citedreferenceHudson JQ, McNeely EB, Green CA, Jennings LK. Assessment of eptifibatide clearance by hemodialysis using an in vitro system. Blood Purif. 2010; 30: 266 – 271.
dc.identifier.citedreferenceSperling RT, Pinto DS, Ho KK, Carrozza JP Jr. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv. 2003; 59: 459 – 462.
dc.identifier.citedreferenceMozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics‐2016 Update: a report from the American Heart Association. Circulation. 2015.
dc.identifier.citedreferenceCapodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012; 125: 2649 – 2661.
dc.identifier.citedreferenceKaw D, Malhotra D. Platelet dysfunction and end‐stage renal disease. Semin Dial. 2006; 19: 317 – 322.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
joic12388.pdf
Size:
972.8KB
Format:
PDF
View/Open
Name:
joic12388_am.pdf
Size:
1.324MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.